Abstract
Breast cancer remains a significant global health challenge, with Matrix metalloproteinase-16 (MMP-16) playing a critical role in tumor invasion. This study investigates the anti-tumor potential of catalpol, a primary active ingredient of Rehmannia. Using MCF-7 breast cancer cells, we evaluated the effects of catalpol on cell proliferation, apoptosis, and the expression of MMP-16 and microRNA-146a (miR-146a). Our results indicate that catalpol significantly inhibits proliferation and promotes apoptosis in a dose-dependent manner. Mechanistically, catalpol upregulates miR-146a, which subsequently downregulates MMP-16 expression. These findings suggest that the miR-146a/MMP-16 axis is a key pathway through which catalpol exerts its therapeutic effects in breast cancer.
Introduction
Breast cancer is the most prevalent malignancy in women and a leading cause of cancer-related mortality. Invasive progression is often facilitated by the degradation of the extracellular matrix, a process mediated by Matrix Metalloproteinases (MMPs). Specifically, MMP-16 has been identified as a potent enhancer of breast cancer cell invasion. Concurrently, microRNAs like miR-146a have emerged as vital regulators of gene expression in cancer pathology. Catalpol, an iridoid glucoside found in Rehmannia, has demonstrated various pharmacological benefits, including anti-tumor properties. This study aims to elucidate whether catalpol can modulate the miR-146a/MMP-16 axis to suppress breast cancer progression.
Methods
The human breast cancer cell line MCF-7 was treated with varying concentrations of catalpol (0, 25, 50, and 100 µg/ml). Cell viability was assessed using the MTT assay (measuring absorbance at 570 nm) over 72 hours. Apoptosis was quantified through Caspase-3 activity assays and flow cytometry. To investigate the molecular mechanism, RT-qPCR was used to measure miR-146a levels, and gelatin zymography/Western blotting assessed MMP-16 activity and expression. Gain-of-function and loss-of-function experiments using miR-146a mimics and inhibitors were conducted to confirm the regulatory relationship between miR-146a and MMP-16.
Results
Inhibition of Proliferation and Induction of Apoptosis
Catalpol treatment resulted in a significant, dose-dependent reduction in MCF-7 cell viability. As shown in the MTT assay results, higher concentrations and longer exposure times led to a marked decrease in A570 nm values. Simultaneously, catalpol induced programmed cell death, evidenced by a significant increase in Caspase-3 activity, particularly at the 50 and 100 µg/ml doses.
Downregulation of MMP-16
A critical finding of this study was the impact of catalpol on the invasive marker MMP-16. Protein expression levels of MMP-16 were significantly reduced following treatment with catalpol. This suppression was most evident at the highest concentration (100 µg/ml), suggesting that catalpol directly interferes with the molecular machinery responsible for tumor invasiveness.
The miR-146a/MMP-16 Regulatory Axis
Molecular analysis revealed that catalpol treatment significantly upregulated the expression of miR-146a. Transfection experiments further demonstrated that overexpressing miR-146a could mimic the effects of catalpol by reducing MMP-16 levels. Conversely, inhibiting miR-146a blocked the ability of catalpol to suppress MMP-16, confirming that miR-146a acts as a necessary intermediary in this therapeutic pathway.
Discussion and Conclusion
This study provides compelling evidence that catalpol acts as a potent anti-proliferative and pro-apoptotic agent in MCF-7 breast cancer cells. By triggering the upregulation of miR-146a, catalpol effectively "silences" the expression of MMP-16, thereby inhibiting the invasive potential of the cells.
While these results are promising, they are currently limited to in vitro observations in a single cell line (MCF-7). Future research should focus on validating these mechanisms in animal models and exploring the efficacy of catalpol against more aggressive, hormone-receptor-negative breast cancer subtypes. In conclusion, catalpol represents a promising natural lead compound for the development of novel breast cancer therapies targeting the miR-146a/MMP-16 axis.
Summary updated